Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP

• Published in: Journal of clinical pathology Vol. 66; no. 5; pp. 420 - 425
• Main Authors: Shim, Hyoeun, Oh, Jae-Il, Park, Sang Hyuk, Jang, Seongsoo, Park, Chan-Jeoung, Huh, Jooryung, Suh, Cheolwon, Chi, Hyun-Sook
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd and Association of Clinical Pathologists 01.05.2013; BMJ Publishing Group LTD
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow - pathology; Child; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - mortality; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Middle Aged; Prednisone; Prognosis; Vincristine; Young Adult

Background Bone marrow involvement confers a poor prognosis in patients with diffuse, large, B-cell lymphoma (DLBCL). However, the prognostic significance of concordant and discordant bone marrow involvement in these cases differs. We analysed this further in patients treated with R-CHOP (rituximab...